Sanjay Asthana, MD, FACP

Associate Dean for Gerontology
Professor and Head, Division of Geriatrics & Gerontology
Director, NIA/NIH Wisconsin Alzheimer’s Disease Research Center (ADRC)
Director, Madison VA Geriatric Research, Education and Clinical Center (GRECC)
Duncan G. and Lottie H. Ballantine Endowed Chair in Geriatrics
University of Wisconsin School of Medicine and Public Health
Madison, WI

Contact Information:
Division of Geriatrics and Gerontology
2870 University Avenue, Suite 106
Madison, WI 53705

Tel: 608-265-5862
Fax: 608-263-7645

Administrative Assistant: Eva Gray Davenport
emgray@medicine.wisc.edu
608-265-5862

Biography
Dr. Asthana received his medical degree at the University College of Medical Sciences, University of Delhi in New Delhi, India and completed his residency training in internal medicine at the University of Saskatchewan School of Medicine in Canada. He obtained his Geriatric Fellowship training at the Johns Hopkins University School of Medicine and completed an additional Senior Staff Fellowship in Alzheimer’s disease research at the Laboratory of Neurosciences of the National Institute on Aging (NIA), National Institutes of Health (NIH) in Bethesda, Maryland. The primary focus of his research is to identify novel antecedent biomarkers for preclinical stages of Alzheimer’s disease (AD). Additionally, he is internationally recognized for his research on estrogen and related hormones for the treatment of AD. For over 20 years, his research program has been supported by multiple peer-reviewed grants from NIH, the US Department of Veterans Affairs, and various philanthropic organizations. He has published over 150 peer-reviewed papers to date, several published in high-profile journals.

Research Interests
Neurobiology of Alzheimer’s Disease and Healthy Aging: Translational and Patient-Oriented Research
• Antecedent biomarkers of preclinical stages of Alzheimer’s disease
• Neuroendocrinology and neurobiology of Alzheimer’s disease
• Cognitive effects and neuroendocrinology of estrogen in Alzheimer’s disease and healthy aging
• Clinical trials of emerging therapies for Alzheimer’s disease

Recent Publications
1. Okonkwo OC, Asthana S. Dementia Trends in the United States: Read Up and Weigh In. JAMA Intern Med. 2017 Jan 1;177(1):58-60. Doi:10.1001/jamainternmed.2016.7073. PMID:27893015.
2. Dean DC 3rd, Hurley SA, Kecskemeti SR, O’Grady JP, Canda C, Davenport-Sis NJ, Carlsson CM, Zetterberg H, Blennow K, Asthana S, Sager MA, Johnson SC, Alexander AL, Bendlin BB. Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. JAMA Neurol. 2017 Jan 1;74(1):41-49. Doi:10.1001/jamaneurol.2016.3232. PMID:27842175.
3. Wang J, Cunningham R, Zetterberg H, Asthana S, Carlsson C, Okonkwo O, Li L. Label-free quantitative comparison of cerebrospinal fluid glycoproteins and endogenous peptides in subjects with Alzheimer’s disease, mild cognitive impairment, and healthy individuals. Proteomics Clin Appl. 2016 Dec;10(12):1225-1241. Doi:10.1002/prca.201600009. PMID: 27863112.
4. Snyder HM, Asthana S, Bain L, Brinton R, Craft S, Dubal DB, Espeland MA, Gatz M, Mielke MM, Raber J, Rapp PR, Yaffe K, Carrillo MC. Sex biology contributions to vulnerability to Alzheimer’s disease: A think tank convened by the Women’s Alzheimer’s Research Initiative. Alzheimers Dement. 2016 Nov; 12(11):1186-1196. Doi:10.1016/j.jalz.2016.08.004. Epub 2016 Sep 27. PMID: 27692800.

(Book Chapters)
1. Carlsson CM, Gleason CE, Puglielli L, Asthana S: “Dementia Including Alzheimer’s Disease” in Hazzard’s Geriatric Medicine and Gerontology. Eds Halter J, Ouslander J, Studenski S, High K, Asthana S, Supiano M, Ritchie C, Woolard N. 7th ed. New York: McGraw-Hill Professional, 2016.
2. Gleason CE, Wharton W, Carlsson CM, Asthana S: “Alternative estrogen treatment regimens and the Kronos Early Estrogen Prevention Study-Cognitive and Affective Substudy (KEEPS-CA)”, in Hormones, Cognition and Dementia: State of the Art and Emergent Therapeutic Strategies. Eds. Hogervorset E, Henderson V, Gibbs R and Brinton R, pp 65-79, Cambridge University Press, UK, 2009.
3. Wharton W, Asthana S, Gleason CE: The use of transdermal 17 β-estradiol in the treatment of Alzheimer’s disease, in Hormones, Cognition and Dementia: State of the Art and Emergent Therapeutic Strategies. Eds. Hogervorset E, Henderson V, Gibbs R and Brinton R, pp 80-86, Cambridge University Press, UK, 2009.
4. Wharton W, Asthana S, Gleason CE: Testosterone therapy and Alzheimer’s disease: Potential for treatment and prevention, in Hormones, Cognition and Dementia: State of the Art and Emergent Therapeutic Strategies. Eds. Hogervorset E, Henderson V, Gibbs R and Brinton R, pp 220-227, Cambridge University Press, UK, 2009.

返回